Basis of selection of first and second line highly active antiretroviral therapy for hiv/aids on genetic barrier to resistance: a literature review. by Katusiime, C et al.
Basis of  selection of  first and second line highly active antiretroviral therapy for hiv/aids 
on genetic barrier to resistance: a literature review.
Christine Katusiime1, Ponsiano Ocama2, Andrew Kambugu1
 
1. Makerere University, College of  Health Sciences, Infectious Diseases Institute, Kampala, Uganda
2. Makerere University, College of  Health Sciences, Department of  Medicine, Kampala, Uganda.
 
Abstract:
The effectiveness of  combination antiretroviral therapy (cART) continues to improve as treatment choices expand with 
the development of  new antiretroviral agents and regimens. However, the successful long-term treatment of  HIV/AIDS is 
under threat from the emergence of  drug-resistant strains to multiple agents and entire drug classes. 
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Introduction
Long-term management of  HIV/AIDS is at risk of  
increasing drug resistance(1). Booster protease inhibi-
tor (PI) and thymidine analogue-containing regimens 
have a high genetic barrier to resistance (25). Non-thy-
midine-analogue triple nucleoside/nucleotide reverse 
transcriptase inhibitor (NRTI/NtRTI) combination 
regimens and Non-nucleoside reverse transcriptase in-
hibitors on the contrary have a low genetic barrier to 
resistance (6-9). 
Unfortunately, several low genetic barrier agents select 
for mutations that confer broad class resistance (10, 
11). The selection of  the K103N and Y181C mutations 
cause loss of  activity to all currently available NNRTIs. 
Most NRTIs are rendered inactive by the selection of  
the K65R mutation (12). The M184V mutation in ad-
dition causes loss of  activity to both lamivudine (3TC) 
and emicitrabine (FTC), but has been shown to con-
fer viral resensitisation to zidovudine (ZDV), stavudine 
(d4T) and tenofovir (TDF) (12) and delay in thymidine 
analogue mutations (TAMs) emergence (5). L74V mu-
tation selection causes decreased antiviral activity of  
abacavir (ABC), didanosine (ddI), and zalcitabine (ddC), 
and when the mutated virus is selecting for both L74V 
and M184V, only the thymidine analogues (ZDV and 
d4T) and TDF retain susceptibility (12). In this paper, 
we review literature focusing on the genetic barrier to 




A search of  the SCOPUS and MEDLINE databases for 
articles on commonly used HAART and genetic barrier 
was done. The keyword ‘genetic barrier’ was cross-ref-
erenced with the keywords ‘HIV’ and ‘HIV resistance’. 
Secondary references were also reviewed. Results were 
restricted to articles published in English between 1980 
and 2009. The year 1980 was selected as the beginning 
of  the period of  interest to ensure that we captured an 
adequate amount of  published literature. 
 
Results
Based on the search terms, the searches yielded 185 
articles eligible for inclusion. After titles and abstracts 
were reviewed, only 22 articles were reviewed in full, of  
which 9 presented data sufficient for inclusion in the 
final analysis. 
Discussion
With growing access to CART in low-resource set-
tings, treatment options in terms of  better and less 
toxic medications is also increasing. Table I shows 
different literature discussing genetic barriers of  vari-
ous commonly used cART with their corresponding 
virologic suppression rate. The decision to use low or 
high genetic antiretroviral regimens as initial cART in 
treatment naïve patients is not definitive and is largely 
governed by availability especially in resource-limited 
settings. Booster PI-based regimens generally have a 
high genetic barrier to resistance (1,13,15,16,18-20) and 
are recommended for use but gastrointestinal adverse 
drug effects precludes their use as first line therapy and 
is mainly reserved for second line therapy21. Selection 
of  low genetic barrier combinations on the contrary, 
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may result into broad class resistance hence reducing 
treatment options10, 11. Genetic barrierinformation 
however, may provide guidance to health workers on 
the selection of  optimal cART regimens to improve 
the durability of  CART and therefore ensure treatment 
success. Combinations of  both low and high genetic 
barrier ART drugs are recommended. These combina-
tions of  high and low genetic barrier ART may produce 
potent first-line therapy. The ramification of  potent 
cART is effective virologic control which is not easily 




Different regimens have different genetic barriers to 
resistance and the recommendation would be to use 
combinations of  low and high genetic barrier drugs for 
instance ZDV in combination with low genetic barrier 
drugs as first-line therapy. Use of  low genetic barrier 
regimens as first line therapy confers broad class resist-
ance over more than one group of  ARVs. Use of  high 
genetic barrier regimens as first line therapy on the con-
trary, requires a number of  mutations to be rendered 
inactive and therefore will allow clinicians to be able to 
provide both support and adherence counselling so as 
to ensure treatment success for subsequent regimens.
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